Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.51 per share which missed the analyst consensus estimate of $2.70 by 7.04 percent. This is a 13.45 percent decrease over earnings of $2.90 per share from the same period last year. The company reported quarterly sales of $693.200 million which beat the analyst consensus estimate of $688.758 million by 0.64 percent. This is a 3.85 percent increase over sales of $667.500 million the same period last year.